This story is a reprint from Kyowa Kirin Annual Report 2022. Click herePDF file to read more on Annual Report 2022.

We believe that ensuring the stable supply of high-quality pharmaceuticals is vital for a pharmaceutical company.
Having the highest level of Quality and a Stable Supply of products are very important management imperatives, therefore, Kyowa Kirin is advancing various initiatives toward these priorities.

Capital investment in Takasaki Plant aimed at stable supply

Kyowa Kirin has two key production bases, in Takasaki City, Gunma Prefecture, and Ube City, Yamaguchi Prefecture. Primarily a base for biopharmaceuticals, the Takasaki area is home to the Bio Process Research and Development Laboratories, which develop production technologies and handle regulatory filings, and the Takasaki Plant, which manufactures and formulates bulk pharmaceuticals for investigational drugs and marketed products. Taking advantage of their geographical proximity, our teams work closely together. Such collaboration makes this location a world-class biopharmaceutical research and manufacturing base.

Q-TOWER completed

In 2022, the Q-TOWER that was being built at the Takasaki Plant was completed. The new Quality building is fully compliant with Japan, the United States, and European Good Manufacturing Practices (GMP). The Q-TOWER was newly constructed to carry out Quality operations relating to quality control and quality assurance, such as the testing of biopharmaceuticals and raw material quality analysis. This new quality building is equipped with the most advanced biopharmaceutical analysis equipment, including an automated colony counter, rapid microbial testing, and robot technology. As well as equipment to automate processes and reduce manpower, such as a liquid handling system and an automated sample picking system.


Also, a sterility testing isolator has been installed, helping create a laboratory that satisfies the latest global regulations. By having designed workspace areas with spatial continuity, we are providing an environment in which everyone can work healthily, creatively, and truly have an optimal workplace for fostering a positive culture.

Construction of a biopharmaceutical drug substance manufacturing building and new warehouse building planned

In 2022, the Company decided to construct a new biopharmaceutical drug substance manufacturing building and a new warehouse building at its Takasaki Plant.

Manufacturing biopharmaceutical drug substances for biopharmaceuticals utilizing Kyowa Kirin’s unique antibody technology and protein engineering, the new HB7 Building will be equipped with both a GMP facility to manufacture biopharmaceutical drug substances for use in GMP-compliant clinical trials and a pilot facility for the scaled-up verification of manufacturing methods established in our laboratories. As both facilities have been designed to have the same single-use manufacturing equipment, and the same facility configuration can be used for everything, from the initial process development of biopharmaceutical drug substance manufacturing to the manufacturing of investigational biopharmaceutical drug substances, it will be possible to manufacture high-mix, small-lot products in early phase development more flexibly and quickly. Moreover, it is planned to use the pilot facility to verify the continuous production system, which is new technology for biopharmaceutical drug substances, as part of efforts to promote technological innovation directed at stable supply.

Rendering of the exterior of the new biopharmaceutical drug substance manufacturing building

Biopharmaceutical drug substance production facilities

The new warehouse building will be constructed to accommodate the expanding supply of biopharmaceuticals (products and development). The regulatory authorities in various countries require that strict control measures be in place for the storage of pharmaceutical raw materials, biopharmaceutical drug substances, and formulations. For that reason, the new warehouse building will comply with the standards required by each regulatory authority and be capable of stably storing biopharmaceutical raw materials, biopharmaceutical drug substances, and formulations at room, cold or frozen temperatures. The building will also have a seismic isolation structure that will enable continuous product supply and the early resumption of production even in the event of a major disaster, such as an earthquake or flood. It is assumed that key facilities will be designed to protect them from any damage caused by flooding. In addition, the facility’s environmental friendliness is being taken into consideration by installing a solar power generation system on the rooftop and actively adopting energy-efficient air conditioning equipment.

Building a world-class Quality Assurance (QA) system

Pharmaceuticals are products that directly affect human lives. At a pharmaceutical company, quality is the responsibility of every employee. Without robust quality and compliance, we cannot earn the trust of patients, healthcare professionals, national regulatory authorities nor that of society. Kyowa Kirin’s Global QA Function confirms that various processes, including manufacturing and distribution, are conducted properly and in compliance with relevant laws and regulations. Our overall aim within the Global QA function is to always ensure the highest quality medicines are delivered to our patients that are in need.

Enterprise/Electronic Quality Management System (eQMS)

Since 2019, when globalization began in earnest, we have been formulating the Kyowa Kirin Group Quality Policy and the Global Quality Roadmap to 2025 while steadily strengthening our global QA system. In 2022, we completed the introduction of an enterprise/electronic quality management system (eQMS). By having introduced this system, which covers a wide range of quality assurance operations from deviation control, corrective action/preventive action (CAPA), training, document management, auditing, supplier management, and change management by means of a complete electronic process. We now have in place a platform that enables us to meet globally consistent standards as well as the requirements of relevant laws and regulations for each country and market we serve. Aiming to build a preventive quality management system using risk-based approaches that we can confidently claim to be world-class, we have set globally integrated KPIs. While monitoring operational status in real time, we will gather and analyze vast amounts of data collected as well as engage in continuous improvement of processes and the fostering of a quality culture routinely.

Supply Chain Management (SCM) and other initiatives

The number of countries in which global strategic products such as Crysvita are sold is steadily increasing, and the overseas revenue ratio, which was 48% in 2020, is expected to reach 64% in 2023. In accordance with this expansion, the supply chain related to manufacturing and distribution, including outsourcing, is becoming more and more complex, and Kyowa Kirin is focusing on its management.

Kyowa Kirin’s SCM Function is responsible for accurately monitoring and controlling this complex situation so that our pharmaceutical products reach the patients who need them, when they need them, and in precisely the quantity needed. To control the supply-demand balance with a high degree of precision, the SCM Function serves as a coordinator, building strong partnerships internally in particular with the quality assurance, production, and sales functions as well as externally with contract manufacturing companies and logistics companies. At the same time, by further evolving S&OP* initiatives, the SCM Function helps to optimize inventory levels while supporting rapid decision-making by management.

Following the disruption caused by the COVID-19 pandemic that began in 2020, transportation risks arose in 2022 due to the Russia-Ukraine conflict, but Kyowa Kirin has continued to maintain stable supplies through SCM Function-centered cooperation and response. For the Company to keep this up going forward, in addition to early anomaly detection and continuous improvement through supply chain KPI monitoring, we are planning a raft of measures designed to maintain a stable supply. These measures include building and updating stable supply Business Continuity Plans (BCPs) and the dispersing of our storage locations for drug substances over multiple sites. We will also further expand measures to counter the problem of counterfeit drugs, which has become increasingly serious in recent years, and contribute to the creation of an environment in which patients can receive treatment with peace of mind.

  • *
    Abbreviation for Sales and Operations Planning. A system that enables sales and production/operational divisions to confirm plans and results, both in quantitative and monetary terms. S&OP ensures alignment on the optimal plan for the Company, increasing the accuracy and speed of decision making to support the achievement of the Company’s financial targets.

More Kyowa Kirin "Sustainability" Stories

Kyowa Kirin Global Corporate Planning Head Shoko Itagaki’s Message for International Women's Day

People & Culture | March 8, 2024

Kyowa Kirin celebrates Rare Disease Day 2024 across the world

Patients | February 9, 2024

Kyowa Kirin CEO Miyamoto’s New Year Message

Growth | January 9, 2024

Kyowa Kirin Chief International Business Officer Abdul Mullick’s Message on UN’s International Day of Persons with Disabilities

Sustainability | December 1, 2023

Kyowa Kirin hosted a booth for the first time at the Tokyo Rainbow Pride 2023 [Our Diversity, Equity & Inclusion]

People & Culture | November 9, 2023

Our Stable Supply of High-quality Pharmaceuticals

Sustainability | September 20, 2023

Provide pharmaceuticals for unmet medical needs - A Conversation with Kyowa Kirin’s R&D Executives

Innovation | August 22, 2023PDF file

Ensure a Thriving Global Environment for Future Generations

Sustainability | July 28, 2023

“Menstruation” and “fertility treatment” felt like taboo subjects in the workplace - Why be open about issues unique to women? PartⅡ

People & Culture | June 9, 2023

How Kyowa Kirin Celebrated Rare Disease Day 2023 around The World

Patients | May 18, 2023

“Menstruation” and “fertility treatment” felt like taboo subjects in the workplace - Why be open about issues unique to women? PartⅠ

People & Culture | April 25, 2023

Kyowa Kirin CEO Miyamoto’s Message on Rare Disease Day

Patients | February 28, 2023

Promoting patient advocacy and nurturing patient-centric care: Interview with Kyowa Kirin North America

Patients | February 14, 2023

Celebrating another year of diverse initiatives around the world: RDD 2022 in EMEA

Patients | January 24, 2023

Celebrating another year of diverse initiatives around the world: RDD 2022 in North America

Patients | December 15, 2022

Celebrating another year of diverse initiatives around the world: RDD 2022 in Asia Pacific

Patients | November 21, 2022

Celebrating another year of diverse initiatives around the world: RDD 2022 in Japan

Patients | October 20, 2022

Providing high-quality pharmaceuticals to patients around the world

Sustainability | September 22, 2022

Striving to create life-changing “Only-one value” that brings smiles to patients

Innovation | July 25, 2022

Kyowa Kirin International: It's Time to Shine A Light on XLH

Patients | June 27, 2022

Kyowa Kirin CEO Miyamoto’s Message on Pride Month

People & Culture | June 9, 2022

Kyowa Kirin International Celebrates the UN’s International Day of Persons with Disabilities in EMEA

People & Culture | January 20, 2022

Kyowa Kirin International: Around the world challenge

People & Culture | December 17, 2021Open in new window

Kyowa Kirin North America: Honoring The Caregiver, Everyday Heroes, During National Family Caregivers Month

Patients | November 19, 2021

Kyowa Kirin's Effort to Realize a Sustainable Society

Sustainability | October 11, 2021

Our Financial Strategy for Creating Life-changing Value

Growth | September 9, 2021

Changes in society caused by COVID-19 and the impact on Kyowa Kirin

Growth | August 19, 2021

Bio Adventure Hands-On Experience Sessions: Become a drug discovery researcher During Your Summer Break

Sustainability | July 27, 2021


News Release | June 1, 2021

MEI Pharma and Kyowa Kirin Announce New Clinical Data on Zandelisib at American Society of Clinical Oncology Annual Meeting

News Release | May 20, 2021

White Paper on the unrecognized burden of XLH in adults in Europe

Patients | July 13, 2020

Empowering Children to Ask "Why?": Tohoku University Science Campus Hands-On Science Lessons (First Half)

People & Culture | March 5, 2020

Empowering Children to Ask "Why?": Tohoku University Science Campus Hands-On Science Lessons (Second Half)

People & Culture | March 5, 2020

“Delivering smiles with sports” Creating an inclusive society through table tennis

Sustainability | January 14, 2020

Bio Adventure*: Kyowa Kirin Invites Children to a Science Adventure

People & Culture | July 3, 2019

Return to Stories